The purpose of these guidelines is to ensure compliance with the scope and requirements of
Regulation (EC) No 1920/2006 as amended by Regulation (EU) 2017/2101 in respect to the second
step of the framework, i.e. the risk assessment procedure for and reporting on new psychoactive
substances (Article 5c), and with Council Framework Decision 2004/757/JHA as amended by Directive
(EU) 2017/2103. The text therefore includes appropriate references to the legal framework. To
operationalise the technical aspects of the risk assessment, the guidelines are supported by a set of
guidance notes developed by the EMCDDA. The guidance notes will be adapted as required in order
to reflect developments in the field of new psychoactive substances and risk assessment